Model-based projections of the population-level impact of hepatitis A vaccination in Mexico
Open Access
- 1 August 2012
- journal article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 8 (8) , 1099-1108
Abstract
There are indications of a shift in the pattern of hepatitis A (HAV) in Mexico from high to intermediate endemicity, progressively increasing the mean age of infection and the proportion of cases which are symptomatic. This study estimated the potential impact of universal infant HAV vaccination in Mexico with two doses of Havrix™ at 12 and 18 mo of age on all HAV infections and symptomatic HAV infections. We developed a dynamic transmission model that accounts for changes in demography and HAV epidemiology. It was calibrated using Mexican age-specific seroprevalence and symptomatic HAV incidence data. With 70% first-dose coverage and 85% second-dose coverage, the calibrated model projected that HAV vaccination would reduce the incidence of all HAV infections (symptomatic and asymptomatic) after the first 25 y of vaccination by 71–76% (minimum and maximum for different transmission scenarios). The projected reduction in cumulative incidence of symptomatic HAV infections over the first 25 y of vaccination was 45–51%. With 90% first-dose coverage and 85% second-dose coverage, the projected reduction in incidence of all HAV infections was 85–93%, and the projected reduction in the cumulative incidence of symptomatic HAV infections was 61–67%, over a 25-y time frame. Sensitivity analyses indicated that second-dose coverage is important under the conservative base-case assumptions made about the duration of vaccine protection. The model indicated that universal infant HAV vaccination could substantially reduce the burden of HAV disease in Mexico.Keywords
This publication has 24 references indexed in Scilit:
- Antibody persistence and immune memory in healthy adults following vaccination with a two‐dose inactivated hepatitis A vaccine: Long‐term follow‐up at 15 yearsJournal of Medical Virology, 2011
- Hepatitis A virus seroprevalence by age and world region, 1990 and 2005Vaccine, 2010
- Strengthening preventive care programs: a permanent challenge for healthcare systems; lessons from PREVENIMSS MéxicoBMC Public Health, 2010
- Incidence of Hepatitis A in Argentina after vaccinationJournal of Viral Hepatitis, 2008
- Long‐term trends in hepatitis A incidence following the inclusion of Hepatitis A vaccine in the routine nationwide immunization programJournal of Viral Hepatitis, 2008
- Cost-utility of universal hepatitis A vaccination in CanadaVaccine, 2007
- The cost-effectiveness of universal vaccination of children against hepatitis A in Argentina: results of a dynamic health–economic analysisJournal of Gastroenterology, 2007
- Seroepidemiology of hepatitis A in Mexico: a detector of social inequity and monitor of immunization policiesSalud Pública de México, 2007
- A Mathematical Model of Hepatitis A Transmission in the United States Indicates Value of Universal Childhood ImmunizationClinical Infectious Diseases, 2006
- Kinetics of maternal hepatitis a antibody decay in infants: implications for vaccine useThe Pediatric Infectious Disease Journal, 2002